Nelarabine: Difference between revisions
m (Protected "Nelarabine": Protecting pages from unwanted edits ([edit=sysop] (indefinite) [move=sysop] (indefinite))) |
m (Robot: Automated text replacement (-{{SIB}} +, -{{EH}} +, -{{EJ}} +, -{{Editor Help}} +, -{{Editor Join}} +)) |
||
| Line 20: | Line 20: | ||
}} | }} | ||
{{SI}} | {{SI}} | ||
==Overview== | ==Overview== | ||
| Line 35: | Line 35: | ||
{{Chemotherapeutic agents}} | {{Chemotherapeutic agents}} | ||
[[Category:Chemotherapeutic agents]] | [[Category:Chemotherapeutic agents]] | ||
{{WH}} | {{WH}} | ||
{{WikiDoc Sources}} | {{WikiDoc Sources}} | ||
Revision as of 14:13, 20 August 2012
| File:Nelarabine.svg | |
| Clinical data | |
|---|---|
| Pregnancy category |
|
| Routes of administration | Intravenous |
| ATC code | |
| Legal status | |
| Legal status |
|
| Pharmacokinetic data | |
| Bioavailability | n/a |
| Protein binding | <25% |
| Metabolism | By adenosine deaminase, to 9-β-D-arabinofuranosylguanine |
| Elimination half-life | 30 minutes (nelarabine) 3 hours (ara-G) |
| Excretion | Renal |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| E number | {{#property:P628}} |
| ECHA InfoCard | {{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value). |
| Chemical and physical data | |
| Formula | C11H15N5O5 |
| Molar mass | 297.268 g/mol |
|
WikiDoc Resources for Nelarabine |
|
Articles |
|---|
|
Most recent articles on Nelarabine |
|
Media |
|
Evidence Based Medicine |
|
Clinical Trials |
|
Ongoing Trials on Nelarabine at Clinical Trials.gov Clinical Trials on Nelarabine at Google
|
|
Guidelines / Policies / Govt |
|
US National Guidelines Clearinghouse on Nelarabine
|
|
Books |
|
News |
|
Commentary |
|
Definitions |
|
Patient Resources / Community |
|
Patient resources on Nelarabine Discussion groups on Nelarabine Patient Handouts on Nelarabine Directions to Hospitals Treating Nelarabine Risk calculators and risk factors for Nelarabine
|
|
Healthcare Provider Resources |
|
Causes & Risk Factors for Nelarabine |
|
Continuing Medical Education (CME) |
|
International |
|
|
|
Business |
|
Experimental / Informatics |
Overview
Nelarabine is a chemotherapy drug used in T-cell acute lymphoblastic leukemia. It was previously known as 506U78.
Nelarabine is a purine nucleoside analog converted to its corresponding arabinosylguanine nucleotide triphosphate (araGTP), resulting in inhibition of DNA synthesis and cytotoxicity. Pre-clinical studies suggest that T-cells are particularly sensitive to nelarabine. In October 2005, it was approved by the FDA for T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma that has not responded to or has relapsed following treatment with at least two chemotherapy regimens. Complete responses have been achieved with this medication.
It is marketed as Arranon by GlaxoSmithKline.
External links
- Pages with script errors
- Pages with broken file links
- E number from Wikidata
- ECHA InfoCard ID from Wikidata
- Chemical articles with unknown parameter in Infobox drug
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Articles containing unverified chemical infoboxes
- Chemotherapeutic agents